Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - bifidobacterium bifidum; enterococcus faecium; lactobacillus delbrueckii subspecies bulgaricus; lactobacillus acidophilus; lactobacillus plantarum; lactobacillus rhamnosus; streptococcus salivarius subspecies thermophilus - oral solution/suspension - bifidobacterium bifidum biological-organism active 0.0 p; enterococcus faecium biological-organism active 0.0 p; lactobacillus delbrueckii subspecies bulgaricus biological-organism active 0.0 p; lactobacillus acidophilus biological-organism active 0.0 p; lactobacillus plantarum biological-organism active 0.0 p; lactobacillus rhamnosus biological-organism active 0.0 p; streptococcus salivarius subspecies thermophilus biological-organism active 0.0 p - nutrition & metabolism - animal | birds | cage birds | calf | cat | cattle | dog | dog - puppy | goat | goat kid | horse | horse foal | kitten | lamb | p - establishment of gut microflora | intestinal dysfunction | productivity improvements | promote animal growth | reduced mortality | re-establishment of gut microflora | feed conversion | finishing | following antibiotic use | growth promotion | growth rate | improving feed efficiency | increasing rate of weight gain | liveweight gain | post-antibiotic therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lymecycline 408mg equivalent to 300 mg tetracycline base - capsule - 300 mg - active: lymecycline 408mg equivalent to 300 mg tetracycline base excipient: erythrosine gelatin hydrated silica indigo carmine magnesium stearate quinoline yellow sulfur dioxide titanium dioxide - tetralysal is a broad spectrum antibiotic and is recommended for the treatment of all infections caused by tetracycline sensitive organisms and may be utilised in all conditions where tetracycline therapy is indicated. in common with other tetracyclines it is indicated in penicillin-sensitive patients for the treatment of staphylococcal infections. typical infections include: ear, nose and throat infections; acute and chronic bronchitis (including prophylaxis); infections of the gastrointestinal and urinary tracts; non-gonococcal urethritis of chlamydial origin; and other chlamydial infections such as trachoma; acne; rickettsial fevers; soft tissue infections.

Israel - English - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - solution for injection - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ≥6 months, and for the prevention and treatment of ponv in children aged ≥ 1 month.

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - metronidazole - solution for infusion - metronidazole 500 mg / 100 ml - metronidazole - metronidazole - treatment and prophylaxis of infection which are or may be due to anerobic bacteria,especially bacteriodes species,including bacteriodes fragilis, fusobacterium,eurobacterium and clostridium species.

Israel - English - Ministry of Health

megapharm ltd - trabectedin - powder for concentrate for solution for injection - trabectedin 1 mg/vial - trabectedin - trabectedin - yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - idarubicin hydrochloride - powder for concentrate for solution for infusion - idarubicin hydrochloride 10 mg/vial - idarubicin - idarubicin - antimitotic and cytotoxic agent. acute non-limphocytic leukemia (anll) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.acute limphocytic leukemia (all) as second line treatment in adults and children.

Israel - English - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - film coated tablets - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting .• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - bevacizumab - carcinoma, non-small-cell lung; breast neoplasms; ovarian neoplasms; colorectal neoplasms; carcinoma, renal cell - antineoplastic agents - bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status.bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with avastin in combination with capecitabine. for further information as to her2 status.bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations.bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents.bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents.bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

European Union - English - EMA (European Medicines Agency)

norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastic agents - paxene is indicated for the treatment of patients with:• advanced aids-related kaposi's sarcoma (aids-ks) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (mbc) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (aoc) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (moc) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (nsclc) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. limited efficacy data supports this indication (see section 5.1).

European Union - English - EMA (European Medicines Agency)

clinigen healthcare b.v. - dexrazoxane hydrochloride - extravasation of diagnostic and therapeutic materials - all other therapeutic products - savene is indicated for the treatment of anthracycline extravasation.